Advertisement

International Journal of Hematology

, Volume 78, Issue 5, pp 457–460 | Cite as

Successful Unrelated Cord Blood Transplantation in an Infant with Wiskott-Aldrich Syndrome following Recurrent Cytomegalovirus Disease

  • Michiya Kaneko
  • Tsutomu Watanabe
  • Hiroyoshi Watanabe
  • Masahiro Kimura
  • Hiroko Suzuya
  • Yasuhiro Okamoto
  • Ryuji Nakagawa
  • Yasuhiro Kuroda
Case Report

Abstract

We describe successful unrelated cord blood transplantation in a 14-month-old boy with Wiskott-Aldrich syndrome. He had been suffering from recurrent cytomegalovirus (CMV) pneumonia. Ganciclovir was given pretransplantation and posttransplantation, and CMV antigenemia was monitored as a marker of reactivation. The conditioning regimen was cyclophos-phamide, busulfan, and antithymocyte globulin. The patient received an HLA 1-locus-mismatched cord blood unit, and the total number of infused nucleated cells was 9.0 X 107/kg. Neutrophil engraftment was achieved on day +20, and a platelet count greater than 50 X 109/L was achieved on day +51. A normal lymphoproliferative response to phytohemagglutinin mitogen was detectable 7 months posttransplantation. Long-term use of ganciclovir prevented CMV reactivation and did not compromise engraftment.

Key words

Cord blood transplantation Wiskott-Aldrich syndrome Cytomegalovirus pneumonia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiin- stitutional survey of the Wiskott-Aldrich syndrome.J Pediatr. 1994; 125:876–885.CrossRefPubMedGoogle Scholar
  2. 2.
    Derry JM, Ochs HD, Francke U, et al. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome.Cell. 1994;78:635–644.CrossRefPubMedGoogle Scholar
  3. 3.
    Klein C, Nguryn D, Liu C, et al. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice.Blood. 2003;101:2159–2166.CrossRefPubMedGoogle Scholar
  4. 4.
    Filipovich AH, Stone JV,Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program.Blood. 2001;97:1598–1603.CrossRefPubMedGoogle Scholar
  5. 5.
    Kernan NA, Schroeder ML, Ciavarella D, et al. Umbilical cord blood infusion in a patient for correction of Wiskott-Aldrich syndrome.Blood Cells. 1994;20:245–248.PubMedGoogle Scholar
  6. 6.
    Knutsen AP, Steffen M, Wassmer K, Wall DA. Umbilical cord blood transplantation in Wiskott Aldrich syndrome.J Pediatr. 2003; 142:519–523.CrossRefPubMedGoogle Scholar
  7. 7.
    Zaia JA. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation.Bone Marrow Transplant. 2002;29:633–638.CrossRefPubMedGoogle Scholar
  8. 8.
    Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.N Engl J Med. 1995;334:1038–1044.CrossRefGoogle Scholar
  9. 9.
    Cairo MS, Wagner JE. Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cell for transplantation.Blood. 1997;90:4665–4678.PubMedGoogle Scholar
  10. 10.
    Grewal SS, Baker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?Blood. 2003;101:4233–4244.CrossRefPubMedGoogle Scholar
  11. 11.
    Knutsen AP, Wall DA. Umbilical cord blood transplantation in severe T-cell immunodeficiency disorders: two-year experience.J Clin Immunol. 2000;20:466–476.CrossRefPubMedGoogle Scholar
  12. 12.
    Thomson BG, Robertson KA, Gowan D, et al. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation.Blood. 2000;96: 2703–2711.PubMedGoogle Scholar
  13. 13.
    Moretta A, Maccario R, Fagioli F, et al. Analysis of immune reconstitution in children undergoing cord blood transplantation.Exp Hematol. 2001;29:371–379.CrossRefPubMedGoogle Scholar
  14. 14.
    Burns LJ, Miller W, Kandaswarny C, et al. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus anti- genemia after allogeneic transplantation.Bone Marrow Transplant. 2002;30:945–951.CrossRefPubMedGoogle Scholar
  15. 15.
    Verdonck LF, van den Hoek MR, Rozenberg-Arska M, Dekker AW. A risk adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplant.Clin Infect Dis. 1997;24:901–907.CrossRefPubMedGoogle Scholar
  16. 16.
    Tanaka Y, Kanda Y, Kami M, et al. Monitoring of cytomegalovirus infection by antigenemia assay and two distinct plasma real-time PCR methods after hematopoietic stem cell transplantation.Bone Marrow Transplant. 2002;30:315–319.CrossRefPubMedGoogle Scholar
  17. 17.
    Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study.Blood. 2002;99:1978–1985.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2003

Authors and Affiliations

  • Michiya Kaneko
    • 1
  • Tsutomu Watanabe
    • 1
  • Hiroyoshi Watanabe
    • 1
  • Masahiro Kimura
    • 2
  • Hiroko Suzuya
    • 1
  • Yasuhiro Okamoto
    • 1
  • Ryuji Nakagawa
    • 1
  • Yasuhiro Kuroda
    • 1
  1. 1.Department of PediatricsUniversity ofTokushima School of MedicineTokushimaJapan
  2. 2.Department of PediatricsTakamatsu Red Cross HospitalakamatsuJapan

Personalised recommendations